ADMS Adamas Pharmaceuticals Inc.

6.52
+0.12  (+2%)
Previous Close 6.4
Open 6.45
Price To Book 9.18
Market Cap 181,632,374
Shares 27,857,726
Volume 387,675
Short Ratio
Av. Daily Volume 530,482
Stock charts supplied by TradingView

NewsSee all news

  1. Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

    EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  2. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the

  3. Adamas Reports Third Quarter 2019 Financial Results

    - Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with

  4. Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

    EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after

  5. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Further development deferred - noted May 9, 2019.
ADS-4101
Partial onset seizures in patents with epilepsy
Phase 3 data due 4Q 2019.
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease

Latest News

  1. Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

    EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  2. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the

  3. Adamas Reports Third Quarter 2019 Financial Results

    - Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with

  4. Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

    EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after

  5. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option

  6. Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

    EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  7. Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson's Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

    EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS)

  8. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted its new Chief Executive

  9. Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

    - Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) --

  10. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees the